Logo image of CNS

COHEN & STEERS INC (CNS) Stock Fundamental Analysis

USA - NYSE:CNS - US19247A1007 - Common Stock

70.71 USD
+1.87 (+2.72%)
Last: 10/23/2025, 6:30:00 PM
70.71 USD
0 (0%)
After Hours: 10/23/2025, 6:30:00 PM
Fundamental Rating

5

Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 236 industry peers in the Capital Markets industry. While CNS belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

CNS had positive earnings in the past year.
In the past year CNS has reported a negative cash flow from operations.
Each year in the past 5 years CNS has been profitable.
Each year in the past 5 years CNS had a positive operating cash flow.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1.2 Ratios

CNS has a better Return On Assets (21.59%) than 98.73% of its industry peers.
With an excellent Return On Equity value of 30.67%, CNS belongs to the best of the industry, outperforming 95.34% of the companies in the same industry.
CNS has a Return On Invested Capital of 25.18%. This is amongst the best in the industry. CNS outperforms 98.31% of its industry peers.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.56%.
Industry RankSector Rank
ROA 21.59%
ROE 30.67%
ROIC 25.18%
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

Looking at the Profit Margin, with a value of 29.82%, CNS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
CNS's Profit Margin has declined in the last couple of years.
CNS has a Operating Margin of 33.62%. This is in the better half of the industry: CNS outperforms 61.86% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a better Gross Margin (88.71%) than 92.80% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
Industry RankSector Rank
OM 33.62%
PM (TTM) 29.82%
GM 88.71%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

5

2. Health

2.1 Basic Checks

CNS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNS has been increased compared to 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CNS has an Altman-Z score of 10.73. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.73, CNS belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.73
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

CNS has a Current Ratio of 0.87. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS's Current ratio of 0.87 is on the low side compared to the rest of the industry. CNS is outperformed by 63.56% of its industry peers.
A Quick Ratio of 0.87 indicates that CNS may have some problems paying its short term obligations.
The Quick ratio of CNS (0.87) is worse than 63.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.87% over the past year.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.26%.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%

3.2 Future

CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.06% yearly.
Based on estimates for the next years, CNS will show a quite strong growth in Revenue. The Revenue will grow by 8.09% on average per year.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 23.03, the valuation of CNS can be described as rather expensive.
61.02% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (27.67), we can say CNS is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 20.41, the valuation of CNS can be described as rather expensive.
CNS's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.33, CNS is valued at the same level.
Industry RankSector Rank
PE 23.03
Fwd PE 20.41
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

75.42% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.61
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)5.05
PEG (5Y)9.22
EPS Next 2Y8.74%
EPS Next 3Y8.1%

3

5. Dividend

5.1 Amount

CNS has a Yearly Dividend Yield of 3.51%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 8.56, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is a higher than the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 3.51%

5.2 History

The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

CNS pays out 76.12% of its income as dividend. This is not a sustainable payout ratio.
DP76.12%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

COHEN & STEERS INC

NYSE:CNS (10/23/2025, 6:30:00 PM)

After market: 70.71 0 (0%)

70.71

+1.87 (+2.72%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-16 2025-10-16/amc
Earnings (Next)01-20 2026-01-20/amc
Inst Owners60.28%
Inst Owner Change-0.51%
Ins Owners22.51%
Ins Owner Change-0.31%
Market Cap3.61B
Revenue(TTM)552.79M
Net Income(TTM)162.12M
Analysts48
Price Target79.56 (12.52%)
Short Float %7.24%
Short Ratio7.99
Dividend
Industry RankSector Rank
Dividend Yield 3.51%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.12%
Div Incr Years2
Div Non Decr Years2
Ex-Date08-11 2025-08-11 (0.62)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.28%
Min EPS beat(2)-4.27%
Max EPS beat(2)-2.29%
EPS beat(4)0
Avg EPS beat(4)-2.29%
Min EPS beat(4)-4.27%
Max EPS beat(4)-0.35%
EPS beat(8)2
Avg EPS beat(8)-1.05%
EPS beat(12)5
Avg EPS beat(12)0.61%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.33%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE 23.03
Fwd PE 20.41
P/S 6.63
P/FCF N/A
P/OCF N/A
P/B 6.82
P/tB 7.09
EV/EBITDA 17.61
EPS(TTM)3.07
EY4.34%
EPS(NY)3.46
Fwd EY4.9%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS10.66
BVpS10.36
TBVpS9.97
PEG (NY)5.05
PEG (5Y)9.22
Graham Number26.75
Profitability
Industry RankSector Rank
ROA 21.59%
ROE 30.67%
ROCE 32.81%
ROIC 25.18%
ROICexc 30.38%
ROICexgc 34.72%
OM 33.62%
PM (TTM) 29.82%
GM 88.71%
FCFM N/A
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 55.86%
Cap/Sales 1.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z 10.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
EBIT growth 1Y16.09%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y14.36%
FCF growth 1Y-196.88%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-177.85%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%